Direct Drug Analysis in Polymeric Implants Using Desorption Electrospray Ionization - Mass Spectrometry Imaging (DESI-MSI).

bio-erodible implant continuous flow-through cell dissolution (CFT) desorption electrospray ionization (DESI) long-acting parenteral (LAP) mass spectrometry imaging (MSI)

Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
27 May 2020
Historique:
received: 14 11 2019
accepted: 14 04 2020
entrez: 29 5 2020
pubmed: 29 5 2020
medline: 16 3 2021
Statut: epublish

Résumé

Desorption electrospray ionization mass spectrometry imaging (DESI-MSI) coupled with gas-phase ion mobility spectrometry was used to characterize the drug distribution in polymeric implants before and after exposure to accelerated in vitro release (IVR) media. DESI-MSI provides definitive chemical identification and localization of formulation components, including 2D chemical mapping of individual components with essentially no sample preparation. Polymeric implants containing 40% (w/w) entecavir and poly(D,L-lactide) (PLA) were prepared and then exposed to either acidified PBS (pH 2.5) or MeOH:H Bi-phasic release profiles were observed for implants during IVR release using both medias. During the second phase of release, implants exposed to PBS, pH 2.5, released the entecavir faster than the implants exposed to MeOH:H DESI-MSI coupled with ion mobility analysis produced chemical images of the drug distribution on the exterior and interior of cylindrical polymeric implants before and after exposure to various release medias. These results demonstrated the utility of this technique for rapid characterization of drug and impurity/degradant distribution within polymeric implants with direct implications for formulation development as well as analytical method development activities for various solid parenteral and oral dosage forms. These results are especially meaningful since samples were analyzed with essentially no preparative procedures.

Identifiants

pubmed: 32462273
doi: 10.1007/s11095-020-02823-x
pii: 10.1007/s11095-020-02823-x
doi:

Substances chimiques

Drug Implants 0
Polymers 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107

Auteurs

Elizabeth E Pierson (EE)

Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA. elizabeth.pierson@merck.com.

Anthony J Midey (AJ)

Waters Corporation, Beverly, Massachusetts, 01915, USA.

William P Forrest (WP)

Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.

Vivek Shah (V)

Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.

Hernando J Olivos (HJ)

Waters Corporation, Beverly, Massachusetts, 01915, USA.

Bindesh Shrestha (B)

Waters Corporation, Beverly, Massachusetts, 01915, USA.

Ryan Teller (R)

Waters Corporation, Beverly, Massachusetts, 01915, USA.

Seth Forster (S)

Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.

Alena Bensussan (A)

Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.
Department of Chemistry, The University of Texas at Austin, Austin, Texas, 78712, USA.

Roy Helmy (R)

Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.

Articles similaires

Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Semiconductors Photosynthesis Polymers Carbon Dioxide Bacteria
Animals Huntington Disease Mitochondria Neurons Mice
Nanoparticles Needles Polylactic Acid-Polyglycolic Acid Copolymer Polyethylene Glycols Curcumin

Classifications MeSH